Week in Review: China Resources and Charoen Pokphand Join to Launch $300 Million Life Science Fund

Deals and Financings • China Resources Holdings will join with Bangkok's Charoen Pokphand Group to launch $300 million life science fund, based in Hong Kong; • Indivior of the UK out-licensed China rights for its opioid addiction tablet to Zhejiang Pukang Biotech in a $122.5 million deal; • DNAnexus, a California biomedical informatics and DNA data management company, closed a $68 million round from investors including WuXi NextCODE; • HiberCell, a New York City biotech startup, raised $60.75 million in Series A funding, with China investors Hillhouse and 6 Dimensions participating; • Bolt Biotherapeutics of San Francisco completed a $54 million Series B financing led by Hong Kong's Pivotal bioVenture Partners/Nan Fung Life Sciences; • EdiGene, a Beijing-Cambridge, MA gene editing company, completed a $10 Million Series pre-B Plus, led by Shenzhen Green Pine Capital Partners; • Shanghai's MicuRx acquired China rights to an investigational treatment for antibiotic-resistant infections from Recida Therapeutics of the US; • Suzhou GeneQuantum Healthcare formed a collaboration with MITRO Biotech of Nanjing to develop next-gen radionuclide conjugates; Trials and Approvals • Suzhou Innovent Biologics (HK: 01801) was granted NMPA approval to start trials of a PD-1 bi-specific drug for hematological and advanced solid tumors; • CStone Pharma of Suzhou and Nanjing's Impact Therapeutics filed to start trials of a dual drug therapy that combines CStone's PD-L1 mAb with Impact's PARP inhibitor. Disclosure: none. Share this with colleagues: // //